Dermira to present new analysis of glycopyrronium tosylate program at AAD

Dermira announced that new post-hoc analyses from its glycopyrronium tosylate clinical program will be presented in poster format at the 77th Annual Meeting of the American Academy of Dermatology being held in Washington, D.C., March 1-5, 2019.Poster presentations will highlight post-hoc data analyses from the Phase 3 clinical trials evaluating glycopyrronium tosylate in patients 9 years and older with primary axillary hyperhidrosis, commonly referred to as excessive underarm sweating. Two posters will feature new analyses from the ARIDO open-label, Phase 3 extension study and will focus on management of treatment-emergent adverse events, as well as efficacy for patients who were previously treated with vehicle and transitioned to glycopyrronium tosylate in ARIDO. A third poster will highlight data from the ATMOS-1 and ATMOS-2 Phase 3 trials evaluating glycopyrronium tosylate’s benefit in the treatment of primary axillary hyperhidrosis across a variety of sub-populations, including gender, race, and the presence or absence of other sites on the body affected by hyperhidrosis.
https://thefly.com/landingPageNews.php?id=2870239